Segmentectomy and lobectomy confer similar overall survival (OS) and lung cancer-specific survival (LCSS) among patients with primary nonsmall cell lung cancer (NSCLC) of ≤20 mm without lymph node or distant metastasis, a recent study has shown.
Among children with juvenile idiopathic arthritis, the risk of developing uveitis is not greater in those treated with etanercept than in those receiving methotrexate, according to a study presented at the European League Against Rheumatism (EULAR) 2018 Congress.
Fibromyalgia occurs commonly in patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis, with disease activity seemingly greater in the presence of fibromyalgia, a study reports.
A combined regimen of obinutuzumab (a type II anti-CD20 antibody) and chlorambucil shows significant long-term survival benefit over rituximab plus chlorambucil or chlorambucil alone in patients with chronic lymphocytic leukaemia (CLL) and comorbidities who have not been treated previously, according to the final analysis of the CLL11* study presented at EHA 2018.
There appears to be a dose-response protective effect of serum concentrations of 25-hydroxyvitamin D (25(OH)D) on the risk of breast cancer, such that levels of ≥60 ng/mL yield the most protection, according to a recent study.
Treatment with oral thrombopoietin receptor agonist eltrombopag leads to similar platelet counts in patients with chronic immune thrombocytopaenia (cITP) and persistent (per)ITP, according to the results of phase III (EXTEND) and IV studies presented at the 23rd Congress of the European Hematology Association (EHA 2018) held in Stockholm, Sweden.
Lonely people were twice as likely to die from any cause than people who did not feel lonely, according to a study based on a national survey presented at the recent EuroHeartCare 2018 in Dublin, Ireland. Also, loneliness is associated with poorer patient-reported outcomes in terms of mental and physical health in patients with heart disease.
A treatment regimen combining daratumumab plus bortezomib, melphalan and prednisone markedly extends progression-free survival in patients with multiple myeloma, inducing deep responses and demonstrating acceptable tolerability regardless of baseline renal function, according to the results of the phase III ALCYONE study.